| Literature DB >> 26060575 |
Matthew T James1, Neesh Pannu2, Rebecca Barry3, Divya Karsanji3, Marcello Tonelli3, Brenda R Hemmelgarn4, Braden J Manns4, Sean M Bagshaw5, H Tom Stelfox6, Elijah Dixon7.
Abstract
BACKGROUND: The outcomes of acute kidney injury (AKI) are well appreciated. However, valid indicators of high quality processes of care for AKI after major surgery are lacking.Entities:
Keywords: Acute kidney injury; Quality indicators; Surgery
Year: 2015 PMID: 26060575 PMCID: PMC4460967 DOI: 10.1186/s40697-015-0047-8
Source DB: PubMed Journal: Can J Kidney Health Dis ISSN: 2054-3581
Characteristics of panelists (n = 33)
|
| |
|---|---|
| Years in Clinical Practice | |
| <5 | 6 (18) |
| 5-9 | 9 (27) |
| 10-19 | 10 (30) |
| 20-29 | 7 (21) |
| 30-39 | 1 (3) |
| >40 | 0 (0) |
| Primary Area of Specialty | |
| Surgery | 6 (18) |
| Nephrology | 17 (52) |
| Critical Care | 10 (30) |
| Approximate number of patients a year cared for with acute kidney injury | |
| <20 | 1 (3) |
| 20-39 | 9 (27) |
| 45-59 | 4 (12) |
| >60 | 19 (58) |
Figure 1Progress through steps of the literature search and modified Delphi procedure to identify process of care indicators for the identification, prevention and management of acute kidney injury after major surgery.
Figure 2Perceived Validity of Candidate Process of Care Quality Indicators for Prevention and Early Identification of Acute Kidney Injury after Major Surgery. The bars represent the mean scores with 95% confidence intervals. The number in brackets following each indicator represents the percentage of participants that stated they agreed with the indicator in the initial round of questioning, and was presented to participants in the final round. The horizontal line represents the median score for all indicators.
Figure 5Perceived Validity of Candidate Process of Care Quality Indicators for Specialist Consultation for Acute Kidney Injury. The bars represent the mean scores with 95% confidence intervals. The number in brackets following each indicator represents the percentage of participants that stated they agreed with the indicator in the initial round of questioning, and was presented to participants in the final round. The horizontal line represents the median score for all indicators.
Process of care quality indicators identified as having a high degree of validity in the prevention, identification, and management of acute kidney injury (AKI) after major surgery*
|
| |
|---|---|
|
| |
| Obtain a serum creatinine before surgery |
|
| Use isotonic crystalloids to expand intravascular volume during surgery | 29 (97) |
| Monitor serum creatinine daily to identify AKI after surgery | 26 (87) |
| Monitor urine output daily to identify AKI after surgery | 29 (97) |
| Monitor fluid balance daily after surgery | 26 (87) |
| In the absence of volume overload, provide maintenance IV fluids after surgery |
|
| Administer aminoglycosides using single daily dosing in patients at risk of AKI | 25 (83) |
| Discontinue non-steroidal anti-inflammatory drugs prior to surgery | 28 (93) |
| Avoid repeated exposure to iodinated contrast after surgery | 26 (87) |
| Monitor serum creatinine after prescribing a nephrotoxic drug | 29 (97) |
| Avoid hydroxy-ethyl starch for volume expansion in patients with reduced kidney function‡ | 26 (87) |
| Flag patients at high risk of perioperative acute kidney injury in the medical record | 28 (93) |
|
| |
| Perform a urinalysis for investigation of the cause of AKI | 29 (97) |
| Determine the severity of AKI by monitoring serum creatinine daily after the onset of AKI |
|
| Determine the severity of AKI by monitoring urine output daily after the onset of AKI |
|
| Monitor fluid balance daily after the onset of AKI |
|
| Monitor for acid–base disturbances after the onset of AKI | 29 (97) |
| Monitor for hyperkalemia after the onset of AKI |
|
| Provide intravenous crystalloids to optimize hemodynamic status and restore effective circulating volume and blood pressure in patients with AKI and signs of volume depletion |
|
| Avoid non-steroidal anti-inflammatory drugs after the onset of AKI |
|
| Avoid aminoglycosides after the onset of AKI unless no other antibiotics are available | 27 (90) |
| Provide vasopressors/inotropes to patients with AKI and vasomotor shock that does not respond to IV fluids | 29 (97) |
| Review current medications to identify those that are nephrotoxic or require dose adjustment after the onset of AKI |
|
| Avoid diuretics in the absence of volume overload after the onset of AKI |
|
|
| |
| Obtain a serum creatinine before a contrast imaging procedure | 27 (90) |
| Use isotonic crystalloids for prevention in patients at high risk of CI-AKI |
|
| Use the lowest possible dose of iso-osmolar or low-osmolar iodinated contrast media in patients at high risk of CI-AKI |
|
| Withhold NSAIDs and diuretics before contrast administration | 27 (90) |
| Use an imaging test that doesn’t require iodinated contrast administration in patients with AKI | 28 (93) |
|
| |
| An unclear etiology or cause other than pre-renal or acute tubular necrosis is suspected |
|
| Hyperkalemia refractory to medical therapy | 29 (97) |
| AKI that is unresponsive to treatment or worsening | 28 (93) |
| Respiratory compromise due to volume overload in anuric patients | 28 (93) |
| Severe AKI (i.e., KDIGO Stage 3, 3-fold increase in serum creatinine or increase in Scr > 350 μmol/L) | 26 (87) |
| Signs or symptoms of uremia | 29 (97) |
| A patient that may require renal replacement therapy | 27 (90) |
|
| |
| AKI with hemodynamic instability not responding to fluid resuscitation |
|
| Need for renal replacement therapy in hemodynamically unstable patient | 28 (93) |
| Need for intubation or ventilatory support |
|
| Need for vasopressors or inotropes |
|
*All indicators listed in this table achieved high scores for validity based on a mean score >6 on a 7-point Likert scale.
†The number (%) of panelists who scored each indicator ≥ 6 is shown in the column on the right, with the 16 high consensus indicators, for which no panelists assigned a score <6, highlighted in bold.
‡Applicable to all patients since hydroxyl-ethyl starches shown to increase the risk of AKI and renal replacement therapy in all populations (Mutter TC, Ruth CA, Dart AB. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev. 2013 Jul 23;7).